Bausch & Lomb Incorporated

Quick facts

Marketed products

• bepotastine besilate ophthalmic solution
  Bepotastine blocks H1 receptors and inhibits histamine release from mast cells.
• Brimonidine tartrate ophthalmic solution 0.025%
• bromfenac ophthalmic solution
• Bromfenac Ophthalmic Solution B · Ophthalmology
  Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.
• Dexamethasone 0.1% and tobramycin 0.3%
• fluocinolone acetonide intravitreal implant
• Indomethacin ophthalmic solution
• instillation of NOV03
• Ketorolac Ophthalmic Solution · Ophthalmology
  Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.
• Loteprednol and tobramycin · Metabolic
• Loteprednol etabonate 0.2% · Ophthalmology
  Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
• Loteprednol etabonate 0.5% and tobramycin 0.3%
• loteprednol etabonate and tobramycin
• loteprednol etabonate/tobramycin opthalmic suspension · Ophthalmology
  Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis.
• Lumify® · Ophthalmology
  Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness.
• Miebo · Ophthalmology
• Olopatadine 0.1% · Ophthalmology/Allergy
  Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the eye.
• pegaptanib sodium injection · Ophthalmology
  Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye.
• Perfluorohexyloctane ophthalmic solution
• Soothe® Lubricant Eye Drops · Ophthalmology
  Soothe® Lubricant Eye Drops provide ocular surface lubrication and protection by forming a protective film over the cornea and conjunctiva.
• Tobramycin and dexamethasone · Ophthalmology
  Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.
• Tobramycin and dexamethasone ophthalmic suspension · Ophthalmology
  Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.
• Vehicle of Zylet · Ophthalmology
  The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin.
• Vitrase · Other
• Zaditor® · Ophthalmology / Allergy
  Zaditor is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic responses in the eye.

Phase 3 pipeline

• Azopt 1% · Ophthalmology
  Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye.
• Bepotastine besilate formulation · Ophthalmology / Allergy
  Bepotastine besilate is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.
• BOL-303259-X · Ophthalmology
  BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.
• brinzolamide 1% ophthalmic suspension · Ophthalmology
  Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye.
• Bromfenac Ophthalmic Solution A · Ophthalmology
  Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.
• BTOS-HA · Ophthalmology
  BTOS-HA is a hyaluronic acid-based ophthalmic formulation designed to provide sustained lubrication and protection to the ocular surface.
• EM-100 · Ophthalmology
  EM-100 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.
• Experimental: Vehicle ophthalmic solution · Ophthalmology
  A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability.
• ISV-403 · Ophthalmology
  ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.
• KetoNaph · Ophthalmology
  KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye.
• Ketotifen Fumarate 0.035% · Ophthalmology / Allergy
  Ketotifen is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic reactions by blocking histamine release and reducing mast cell degranulation.
• Ketotifen/naphazoline · Ophthalmology / Allergy
  Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while naphazoline is a selective alpha-1 adrenergic agonist, together reducing allergic inflammation and vasoconstriction in the eye.
• NOV03 · Infectious Diseases
  NOV03 is an investigational antiviral medication.
• Prednisolone and Tobramycin · Ophthalmology
  This combination uses prednisolone to suppress inflammation and tobramycin to provide topical antimicrobial coverage, typically for ocular infections or inflammatory conditions.
• Prednisolones acetate · Ophthalmology
  Prednisolone acetate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators.
• T-Pred · Ophthalmology
  T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system.
• Vehicle Gel (BID) · Ophthalmology
  Vehicle Gel is a topical ophthalmic gel used to lubricate and protect the eyes.
• vehicle of loteprednol etabonate · Ophthalmology
  Loteprednol etabonate is a corticosteroid that works by inhibiting the inflammatory response.
• Vehicle of Ophthalmic Loteprednol Etabonate · Ophthalmology
  Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins.
• Vehicle (TID)
  Vehicle (TID) is a treatment that does not have a known mechanism of action.

Phase 2 pipeline

• Bepotastine besilate-fluticasone propionate · Ophthalmology
  Histamine H1 receptor antagonist and corticosteroid combination
• Bepotastine Besilate Nasal Spray 3% Twice a day
• BL1107 High dose · Ophthalmology
  BL1107 High dose is an anti-inflammatory agent.
• BL1107 Low dose
• BOL-303242-X · Ophthalmology
  BOL-303242-X is a small molecule that targets the S1P1 receptor.
• bromfenac ophthalmic solution 0.06%
• corticosteroids and immunosuppressants
• Ecabet 2.83%
• Ecabet 3.70% · Gastrointestinal
  Ecabet is a gastroprotective agent that acts as a mucosal protective agent.
• Loteprednol etabonate suspension
• PF-03187207

Phase 1 pipeline

• Besifloxacin Ophthalmic Suspension 0.6%
• BOL-303224-A
• ISTA Tears
• LE Gel
• WB007 0.05%
• WB007 0.15%
• WB007 0.4%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bausch & Lomb Incorporated portfolio CI brief
• Bausch & Lomb Incorporated pipeline updates RSS